Effect of (-)-epigallocatechin-3-gallate on human insulin fibrillation/aggregation kinetics

Biochemical Engineering Journal

Volumn 63, Issue , 2012, Pages 38-49

  Wang, Shi Hui ^a   Dong, Xiao Yan ^a   Sun, Yan ^a  

^a TIANJIN UNIVERSITY   (China)

Author keywords

( ) Epigallocatechin 3 gallate; Aggregation; Biophysical chemistry; Inhibition; Kinetic parameters; Protein

Indexed keywords

AMYLOID PROTEINS; EPIGALLOCATECHIN-3-GALLATE; GLOBULAR AGGREGATES; GREEN TEA; HEXAMERS; INHIBITORY EFFECT; INSULIN MOLECULES; KINETIC MECHANISM; PHYSICAL MODEL; SECONDARY STRUCTURES; TETRAMERS;

AGGLOMERATION; CIRCULAR DICHROISM SPECTROSCOPY; DIMERS; ENZYME INHIBITION; KINETIC PARAMETERS; KINETICS; MODELS; PROTEINS;

INSULIN;

DIMER; EPIGALLOCATECHIN GALLATE; GLOBULAR PROTEIN; HUMAN INSULIN; MONOMER; TETRAMER;

ARTICLE; CHEMICAL REACTION KINETICS; CIRCULAR DICHROISM; CONCENTRATION (PARAMETERS); FIBER; GEL PERMEATION CHROMATOGRAPHY; HORMONE ACTION; HORMONE STRUCTURE; HUMAN; HYDRODYNAMICS; INSULIN AGGREGATION; INSULIN FIBRILLATION; MOLECULAR INTERACTION; MOLECULAR WEIGHT; PH; PRIORITY JOURNAL; STRUCTURE ANALYSIS;

EID: 84863338398     PISSN: 1369703X     EISSN: 1873295X     Source Type: Journal    
DOI: 10.1016/j.bej.2012.02.002     Document Type: Article

References (46)

1. Harper J.D., Lansbury P.T. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem. 1997, 66:385-407.
2. Murphy R.M. Peptide aggregation in neurodegenerative disease. Annu. Rev. Biomed. Eng. 2002, 4:155-174.
3. Miroy G.J., Lai Z., Lashuel H.A., Peterson S.A., Strang C., Kelly J.W. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:15051-15056.
4. Tartaglia G.G., Pawar A.P., Campioni S., Dobson C.M., Chiti F., Vendruscolo M. Prediction of aggregation-prone regions in structured proteins. J. Mol. Biol. 2008, 380:425-436.
5. Jha S., Sellin D., Seidel R., Winter R. Amyloidogenic propensities and conformational properties of ProIAPP and IAPP in the presence of lipid bilayer membranes. J. Mol. Biol. 2009, 389:907-920.
6. Taylor J.P., Hardy J., Fischbeck K.H. Toxic proteins in neurodegenerative disease. Science 2002, 296:1991-1995.
7. Klabunde T., Petrassi H.M., Oza V.B., Raman P., Kelly J.W., Sacchettini J.C. Rational design of potent human transthyretin amyloid disease inhibitors. Nat. Struct. Biol. 2000, 7:312-321.
8. Yang M., Teplow D.B. Amyloid beta-protein monomer folding: free-energy surfaces reveal alloform-specific differences. J. Mol. Biol. 2008, 384:450-464.
9. Nielsen L., Frokjaer S., Brange J., Uversky V.N., Fink A.L. Probing the mechanism of insulin fibril formation with insulin mutants. Biochemistry 2001, 40:8397-8409.
10. Storkel S., Schneider H.M., Muntefering H., Kashiwagi S. Iatrogenic, insulin-dependent, local amyloidosis. Lab. Invest. 1983, 48:108-111.
11. Dische F.E., Wernstedt C., Westermark G.T., Westermark P., Pepys M.B., Rennie J.A., Gilbey S.G., Watkins P.J. Insulin as an amyloid-fibril protein at sites of repeated insulin injections in a diabetic patient. Diabetologia 1988, 31:158-161.
12. Mauro M., Craparo E.F., Podesta A., Bulone D., Carrotta R., Martorana V., Tiana G., San Biagio P.L. Kinetics of different processes in human insulin amyloid formation. J. Mol. Biol. 2007, 366:258-274.
13. Loksztejn A., Dzwolak W. Vortex-induced formation of insulin amyloid superstructures probed by time-lapse atomic force microscopy and circular dichroism spectroscopy. J. Mol. Biol. 2010, 395:643-655.
14. Astbury W.T., Dickinson S. The X-ray interpretation of denaturation and the structure of the seed globulins. Biochem. J. 1935, 29:2351-2360.
15. Ivanova M.I., Sievers S.A., Sawaya M.R., Wall J.S., Eisenberg D. Molecular basis for insulin fibril assembly. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:18990-18995.
16. Turnell W.G., Finch J.T. Binding of the dye congo red to the amyloid protein pig insulin reveals a novel homology amongst amyloid-forming peptide sequences. J. Mol. Biol. 1992, 227:1205-1223.
17. Malisauskas M., Weise C., Yanamandra K., Wolf-Watz M., Morozova-Roche L. Lability landscape and protease resistance of human insulin amyloid: a new insight into its molecular properties. J. Mol. Biol. 2010, 396:60-74.
18. Teplow D. Structural and kinetic features of amyloid β-protein fibrillogenesis. Amyloid 1998, 5:121-142.
19. Jarrett J., Lansbury P. Seeding one-dimensional crystallization of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie?. Cell 1993, 73:1055.
20. Chen Z., Zhu Q.Y., Tsang D., Huang Y. Degradation of green tea catechins in tea drinks. J. Agric. Food Chem. 2001, 49:477-482.
21. Hasni I., Bourassa P., Hamdani S., Samson G., Carpentier R., Tajmir-Riahi H.A. Interaction of milk alpha- and beta-caseins with tea polyphenols. Food Chem. 2011, 126:630-639.
22. Meng F.L., Abedini A., Plesner A., Verchere C.B., Raleigh D.P. The flavanol (-)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against IAPP-induced toxicity. Biochemistry 2010, 49:8127-8133.
23. Wang S.H., Liu F.F., Dong X.Y., Sun Y. Thermodynamic analysis of the molecular interactions between amyloid beta-peptide 42 and (-)-epigallocatechin-3-gallate. J. Phys. Chem. B 2010, 114:11576-11583.
24. Wang S.-H., Liu F.-F., Dong X.-Y., Sun Y. Calorimetric and spectroscopic studies of the interactions between insulin and (-)-epigallocatechin-3-gallate. Biochem. Eng. J. 2012, 62:70-78.
25. McGraw S.E., Lindenbaum S. The use of microcalorimetry to measure thermodynamic parameters of the binding of ligands to insulin. Pharmaceut. Res. 1990, 7:606-611.
26. Uversky V.N., Fink A.L. Conformational constraints for amyloid fibrillation: the importance of being unfolded. Biochim. Biophys. Acta 2004, 1698:131-153.
27. Militello V., Vetri V., Leone M. Conformational changes involved in thermal aggregation processes of bovine serum albumin. Biophys. Chem. 2003, 105:133-141.
28. Fodera V., Cataldo S., Librizzi F., Pignataro B., Spiccia P., Leone M. Self-organization pathways and spatial heterogeneity in insulin amyloid fibril formation. J. Phys. Chem. B 2009, 113:10830-10837.
29. Nayak A., Lee C.C., McRae G.J., Belfort G. Osmolyte controlled fibrillation kinetics of insulin: new insight into fibrillation using the preferential exclusion principle. Biotechnol. Prog. 2009, 25:1508-1514.
30. Sorci M., Grassucci R.A., Hahn I., Frank J., Belfort G. Time-dependent insulin oligomer reaction pathway prior to fibril formation: cooling and seeding. Proteins 2009, 77:62-73.
31. Nielsen L., Khurana R., Coats A., Frokjaer S., Brange J., Vyas S., Uversky V.N., Fink A.L. Effect of environmental factors on the kinetics of insulin fibril formation: elucidation of the molecular mechanism. Biochemistry 2001, 40:6036-6046.
32. Lee C.C., Nayak A., Sethuraman A., Belfort G., McRae G.J. A three-stage kinetic model of amyloid fibrillation. Biophys. J. 2007, 92:3448-3458.
33. Whittingham J.L., Scott D.J., Chance K., Wilson A., Finch J., Brange J., Dodson G.G. Insulin at pH 2: structural analysis of the conditions promoting insulin fibre formation. J. Mol. Biol. 2002, 318:479-490.
34. Uversky V.N. Use of fast protein size-exclusion liquid chromatography to study the unfolding of proteins which denature through the molten globule. Biochemistry 1993, 32:13288-13298.
35. Arora A., Ha C., Park C.B. Inhibition of insulin amyloid formation by small stress molecules. FEBS Lett. 2004, 564:121-125.
36. Attri P., Venkatesu P., Lee M.J. Influence of osmolytes and denaturants on the structure and enzyme activity of alpha-chymotrypsin. J. Phys. Chem. B 2010, 114:1471-1478.
37. Ehrnhoefer D.E., Bieschke J., Boeddrich A., Herbst M., Masino L., Lurz R., Engemann S., Pastore A., Wanker E.E. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat. Struct. Mol. Biol. 2008, 15:558-566.
38. Carver J.A., Duggan P.J., Ecroyd H., Liu Y., Meyer A.G., Tranberg C.E. Carboxymethylated-kappa-casein: a convenient tool for the identification of polyphenolic inhibitors of amyloid fibril formation. Bioorg. Med. Chem. 2010, 18:222-228.
39. Thapa A., Woo E.R., Chi E.Y., Sharoar M.G., Jin H.G., Shin S.Y., Park I.S. Biflavonoids are superior to monoflavonoids in inhibiting amyloid-beta toxicity and fibrillogenesis via accumulation of nontoxic oligomer-like structures. Biochemistry 2011, 50:2445-2455.
40. Evans K.C., Berger E.P., Cho C.G., Weisgraber K.H., Lansbury P.T. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:763-767.
41. Wisniewski T., Castano E.M., Golabek A., Vogel T., Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am. J. Pathol. 1994, 145:1030-1035.
42. Ma J., Yee A., Brewer H.B., Das S., Potter H. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 1994, 372:92-94.
43. Eriksson S., Janciauskiene S., Lannfelt L. Alpha 1-antichymotrypsin regulates Alzheimer beta-amyloid peptide fibril formation. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:2313-2317.
44. Liu R., He M., Su R., Yu Y., Qi W., He Z. Insulin amyloid fibrillation studied by terahertz spectroscopy and other biophysical methods. Biochem. Biophys. Res. Commun. 2010, 391:862-867.
45. Kanapathipillai M., Lentzen G., Sierks M., Park C.B. Ectoine and hydroxyectoine inhibit aggregation and neurotoxicity of Alzheimer's beta-amyloid. FEBS Lett. 2005, 579:4775-4780.
46. Nieva J., Shafton A., Altobell L.J., Tripuraneni S., Rogel J.K., Wentworth A.D., Lerner R.A., Wentworth P. Lipid-derived aldehydes accelerate light chain amyloid and amorphous aggregation. Biochemistry 2008, 47:7695-7705.